AAPL   324.55 (-0.18%)
MSFT   184.85 (-0.28%)
FB   230.16 (+0.00%)
GOOGL   1,431.67 (-0.53%)
AMZN   2,490.86 (+0.50%)
NVDA   349.86 (-0.26%)
BABA   217.10 (-0.69%)
MU   48.83 (-0.18%)
GE   7.33 (-0.41%)
TSLA   893.10 (+1.15%)
AMD   53.21 (+0.91%)
T   31.37 (-0.48%)
ACB   14.10 (-1.40%)
F   6.21 (+0.32%)
GILD   74.32 (-0.11%)
DIS   122.56 (+0.31%)
NFLX   426.40 (+1.05%)
BAC   25.78 (-0.81%)
BA   184.64 (+6.63%)
AAPL   324.55 (-0.18%)
MSFT   184.85 (-0.28%)
FB   230.16 (+0.00%)
GOOGL   1,431.67 (-0.53%)
AMZN   2,490.86 (+0.50%)
NVDA   349.86 (-0.26%)
BABA   217.10 (-0.69%)
MU   48.83 (-0.18%)
GE   7.33 (-0.41%)
TSLA   893.10 (+1.15%)
AMD   53.21 (+0.91%)
T   31.37 (-0.48%)
ACB   14.10 (-1.40%)
F   6.21 (+0.32%)
GILD   74.32 (-0.11%)
DIS   122.56 (+0.31%)
NFLX   426.40 (+1.05%)
BAC   25.78 (-0.81%)
BA   184.64 (+6.63%)
AAPL   324.55 (-0.18%)
MSFT   184.85 (-0.28%)
FB   230.16 (+0.00%)
GOOGL   1,431.67 (-0.53%)
AMZN   2,490.86 (+0.50%)
NVDA   349.86 (-0.26%)
BABA   217.10 (-0.69%)
MU   48.83 (-0.18%)
GE   7.33 (-0.41%)
TSLA   893.10 (+1.15%)
AMD   53.21 (+0.91%)
T   31.37 (-0.48%)
ACB   14.10 (-1.40%)
F   6.21 (+0.32%)
GILD   74.32 (-0.11%)
DIS   122.56 (+0.31%)
NFLX   426.40 (+1.05%)
BAC   25.78 (-0.81%)
BA   184.64 (+6.63%)
AAPL   324.55 (-0.18%)
MSFT   184.85 (-0.28%)
FB   230.16 (+0.00%)
GOOGL   1,431.67 (-0.53%)
AMZN   2,490.86 (+0.50%)
NVDA   349.86 (-0.26%)
BABA   217.10 (-0.69%)
MU   48.83 (-0.18%)
GE   7.33 (-0.41%)
TSLA   893.10 (+1.15%)
AMD   53.21 (+0.91%)
T   31.37 (-0.48%)
ACB   14.10 (-1.40%)
F   6.21 (+0.32%)
GILD   74.32 (-0.11%)
DIS   122.56 (+0.31%)
NFLX   426.40 (+1.05%)
BAC   25.78 (-0.81%)
BA   184.64 (+6.63%)
Log in

NASDAQ:HRTXHeron Therapeutics Stock Price, Forecast & News

$18.82
+0.29 (+1.57 %)
(As of 06/4/2020 09:42 AM ET)
Add
Compare
Today's Range
$18.59
Now: $18.82
$18.94
50-Day Range
$13.71
MA: $15.69
$19.00
52-Week Range
$9.60
Now: $18.82
$26.81
Volume36,449 shs
Average Volume945,899 shs
Market Capitalization$1.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.55
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy; and HTX-011, an investigational, long-acting, and extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for post-operative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Read More
Heron Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.36 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$145.97 million
Book Value$4.48 per share

Profitability

Net Income$-204,750,000.00
Net Margins-138.31%

Miscellaneous

Employees198
Market Cap$1.71 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

How has Heron Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Heron Therapeutics' stock was trading at $13.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HRTX stock has increased by 37.5% and is now trading at $18.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Heron Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Heron Therapeutics.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Heron Therapeutics.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) issued its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.57) EPS for the quarter, beating the Zacks' consensus estimate of ($0.65) by $0.08. The biotechnology company had revenue of $25.40 million for the quarter, compared to analyst estimates of $21.23 million. Heron Therapeutics had a negative return on equity of 56.85% and a negative net margin of 138.31%. Heron Therapeutics's revenue for the quarter was down 19.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.80) earnings per share. View Heron Therapeutics' earnings history.

What price target have analysts set for HRTX?

10 equities research analysts have issued 1-year price objectives for Heron Therapeutics' stock. Their forecasts range from $24.00 to $75.00. On average, they anticipate Heron Therapeutics' share price to reach $41.50 in the next year. This suggests a possible upside of 121.3% from the stock's current price. View analysts' price targets for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:
  • 1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (5/20/2020)
  • 2. Evercore ISI analysts commented, "We remain highly constructive on the name as ‘011’s differentiated product profile and today’s opioid awareness environment should help propel adoption of the product in a wide range of surgical procedures. We’ve updated the model following earnings; PT remains $75 (OP).  HRTX is confident that the answers to the FDA’s CRL are readily addressed. We will likely see a press release after the NDA is refiled, and the company plans to request a Type A meeting. The key dislocation: the company’s ‘011 timelines have reset, but the commercial opportunity remains unchanged. With the stock trading at these levels, we continue to see substantial upside if the company can execute its launch strategy." (8/13/2019)

Has Heron Therapeutics been receiving favorable news coverage?

News stories about HRTX stock have trended very positive on Thursday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Heron Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutHeron Therapeutics.

Who are some of Heron Therapeutics' key competitors?

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), bluebird bio (BLUE), Gilead Sciences (GILD), Immunomedics (IMMU), Cara Therapeutics (CARA), Amarin (AMRN), Crispr Therapeutics (CRSP), Pfizer (PFE), Seattle Genetics (SGEN) and Inovio Pharmaceuticals (INO).

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the following people:
  • Dr. Barry D. Quart, Pres, CEO & Director (Age 62)
  • Mr. Robert E. Hoffman C.P.A., CPA, CFO & Sr. VP of Fin. (Age 53)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)
  • Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)
  • Mr. Sean T. Ristine, VP of HR (Age 49)

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (14.06%), BlackRock Inc. (6.23%), ArrowMark Colorado Holdings LLC (4.89%), State Street Corp (3.78%), Clearbridge Investments LLC (3.78%) and Janus Henderson Group PLC (3.50%). Company insiders that own Heron Therapeutics stock include Barry D Quart, John Poyhonen, Kevin C Tang, Kimberly Manhard, Robert Hoffman, Robert Rosen and Waage Christian. View institutional ownership trends for Heron Therapeutics.

Which institutional investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Wellington Management Group LLP, Janus Henderson Group PLC, Tang Kevin C, BlackRock Inc., Deutsche Bank AG, Rafferty Asset Management LLC, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Heron Therapeutics.

Which institutional investors are buying Heron Therapeutics stock?

HRTX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Orbimed Advisors LLC, Rothschild & Co. Asset Management US Inc., Sofinnova Investments Inc., Franklin Resources Inc., ArrowMark Colorado Holdings LLC, Morgan Stanley, and Morgan Stanley. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, Kevin C Tang, and Waage Christian. View insider buying and selling activity for Heron Therapeutics.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $18.75.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $1.70 billion and generates $145.97 million in revenue each year. The biotechnology company earns $-204,750,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Heron Therapeutics employs 198 workers across the globe.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is www.herontx.com.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.